Improving vaccines to prevent tuberculosis
ADVANCING VACCINE ADJUVANT RESEARCH FOR TUBERCULOSIS (AVAR-T)
['FUNDING_OTHER'] · UNIVERSITY OF SYDNEY · NIH-10919146
This study is working on creating better vaccines for tuberculosis, especially for people at higher risk like those with HIV, by testing different combinations of ingredients that boost the immune response to find the most effective ones.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF SYDNEY (nih funded) |
| Locations | 1 site (SYDNEY, AUSTRALIA) |
| Trial ID | NIH-10919146 on ClinicalTrials.gov |
What this research studies
This research focuses on developing better vaccines for tuberculosis (TB), particularly for individuals at higher risk, such as those living with HIV. The team will compare different vaccine adjuvants, which enhance the immune response, alongside specific TB antigens to identify the most effective combinations. Using mouse models, they will evaluate these combinations before testing the best candidates in non-human primates. The ultimate goal is to create vaccines that can effectively prevent TB infection and improve treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for tuberculosis, including those living with HIV.
Not a fit: Patients who are not at risk for tuberculosis or who have already been vaccinated with existing TB vaccines may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that significantly reduce the incidence of tuberculosis, especially in vulnerable populations.
How similar studies have performed: Previous research has shown promise in developing vaccine adjuvants for other diseases, indicating potential success for this novel approach in tuberculosis.
Where this research is happening
SYDNEY, AUSTRALIA
- UNIVERSITY OF SYDNEY — SYDNEY, AUSTRALIA (ACTIVE)
Researchers
- Principal investigator: BRITTON, WARWICK — UNIVERSITY OF SYDNEY
- Study coordinator: BRITTON, WARWICK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Disease, Disorder, Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus